ReCode Therapeutics develops gene therapy solutions aimed at treating complex respiratory diseases, specifically cystic fibrosis and primary ciliary dyskinesia. Their approach involves utilizing advanced drug development techniques to create therapies that can effectively target and restore function in patients suffering from these conditions. Unlike many competitors, ReCode Therapeutics emphasizes rapid advancement through a deep understanding of regulatory pathways and clinical trial processes. The company's goal is to overcome challenges in delivering therapies directly to affected areas in the lungs, ultimately enhancing the quality of life for patients with unmet medical needs.

Vida Ventures

Hunt Technology

Colt Ventures

MPM BioImpact

OrbiMed

Cystic Fibrosis Foundation

EcoR1 Capital

Solasta Ventures

Tekla Capital Management

AyurMaya

Osage University Partners

Hunt Technology Ventures

Timefolio Capital

Pfizer Ventures

Sanofi Ventures

Leaps by Bayer

Bioluminescence Ventures

Matrix Capital Management

Amgen Ventures

Superstring Capital

Biotechnology

Healthcare

ReCode Therapeutics 

The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their gene editing collaboration with Intellia

CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences:Wells Fargo Virtual Private Biotech SymposiumFormat: 1x1 Investor MeetingsDate: May 6, 2024Location: VirtualCapital One Biotech - Life Sciences Disruptors EventFormat: Panel Discussion on “The Next Wave of mRNA and Gene Correction Therapeutics”Date: May 14, 2024Time: 1:45 p.m. ETLocation: New YorkVirtual Piper Sandler Lung Day Post-ATSFormat: Fireside ChatDate: May 23, 2024Time: 12:00 – 12:25 p.m. ETLocation: VirtualAbout ReCode TherapeuticsReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform

Recode Therapeutics To Participate In May Conferences

Recode Therapeutics has secured $15 million in funding, led by The Cystic Fibrosis Foundation. The investment will be used to develop a gene editing therapy aimed at delivering treatment to the lung cells of individuals with cystic fibrosis.

Recode Therapeutics Gets $15M Funding

Cystic fibrosis is a condition that causes sticky mucus to build up in the lungs and digestive system. This causes lung infections, problems with digesting food, and severe damage to several organs in the body.There are nearly 40,000 children and adults living with cystic fibrosis in the U.S., according to the Cystic Fibrosis Foundation. In people with the disease, the cystic fibrosis transmembrane conductance regulator (CFTR) gene codes for dysfunctional forms of the CFTR protein. So, when the protein does not do its job properly, it fails to move chloride – present in salt – to the surface of cells. Without chlorine, cell surfaces become dehydrated, resulting in the thick mucus lining in organs. This is why people with cystic fibrosis have a higher-than-normal level of salt in their sweat. CFTR modulators are typically used to treat cystic fibrosis symptoms by correcting the protein

Cystic Fibrosis: Five Biotechs Breathing Life Into The Therapeutic Space

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the appointment of Dean J. Mitchell as chairman of its Board of Directors. Mr. Mitchell is a highly experienced and well-regarded biotechnology and pharmaceutical industry veteran who brings over three decades of experience as a board director and corporate executive to the ReCode board. “We are delighted to have Dean join the board as we continue to advance our respiratory clinical development programs and leverage our novel SORT LNP delivery platform to expand our portfolio,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics. “His proven track record at growing and scaling biopharma companies is a welcome addition to our board that will support the company’s near- and long-term growth.”

Recode Therapeutics Announces Appointment Of Dean J. Mitchell As Chairman Of Its Board Of Directors

ReCode Therapeutics™ (“ReCode”) (“the Company”), a private biopharmaceutical company pioneering precision medicines for pulmonary diseases, today anno

 ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the first cohort of healthy volunteer participants have been dosed in a Phase 1 clinical study of RCT2100, an inhaled mRNA-based investigational therapy for cystic fibrosis (CF) that focuses specifically on the 10-13% of patients with nonsense mutations that do not respond to or experience side effects with, approved CFTR modulators. “The initiation of the clinical study of RCT2100, which is the second candidate developed using our novel Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform, represents an important milestone for the CF community,” stated David Lockhart, Ph.D., chief scientific officer and president, ReCode Therapeutics. “While progress has been made for many people with CF, those who do not benefit from existing modulators report feeling left behind and continue to face profound physical and emotional hardship from the disease. RCT2100 is designed to target the underlying cause of CF so that more people with CF may benefit, including those with rare mutations.”. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and impacts approximately 130,000 people worldwide. Despite advancements in CFTR modulator treatments, no available therapies exist to restore function for Class I mutations in the CFTR gene since those mutations result in no CFTR protein being produced that can be modulated

Recode Therapeutics Announces First Participants Dosed In A Phase 1 Healthy Volunteer Clinical Study Of Inhaled Mrna-Based Genetic Medicine, Rct2100, For The Treatment Of Cystic Fibrosis

CAMBRIDGE, Mass. MENLO PARK, Calif.--(BUSINESS WIRE)--Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF). CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestive systems and other organs. CF can result in life-threatening infections, respiratory failure and other serious complications. The collaboration will leverage Intellia’s proprietary CRISPR-based gene editing platform, including its DNA writing technology, and ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform to precisely correct one or more CF disease-causing gene mutations

Intellia Therapeutics And Recode Therapeutics Announce Strategic Collaboration To Develop Novel Gene Editing Therapies For Cystic Fibrosis

ReCode Therapeutics, a Menlo Park, CA-based clinical-stage genetic medicines company using precision delivery mRNA and gene correction therapeutics, closed an extension to its Series B financing, raising an additional $50m, for a total of $260m

ReCode Therapeutics Raises Additional USD50M in Series B Financing

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023:Morgan Stanley Global Healthcare Conference:Format: Company PresentationDate: September 12, 2023Time: 12:55 p.m. ETPresenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode TherapeuticsLocation: New York, NYJefferies Cell & Genetic Medicine SummitFormat: Company PresentationDate: September 26, 2023Time: 10:30 a.m. ETPresenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode TherapeuticsLocation: New York, NYBMO Biopharma Spotlight Series: Latest Advances in Genome/Epigenome EditingFormat: Panel Discussion - Novel Approaches in Gene Editing and DeliveryDate: September 26, 2023Time: 2:30 p.m. ETPresenter: Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode TherapeuticsLocation: VirtualAbout ReCode TherapeuticsReCode Therapeutics is a clinical-stage company powering the next wave of genetic medicines

Recode Therapeutics To Present At September Investor Conferences

Develops gene therapies for respiratory diseases

ReCode Therapeutics

Develops gene therapies for respiratory diseases

ReCode Therapeutics

Develops gene therapies for respiratory diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes ReCode Therapeutics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

ReCode Therapeutics is Hiring for 0 Jobs on Simplify!